|
||
DAPT+VKA with INR target 2–2.5 | ||
|
||
VKA for a minimum of 3 months | ||
Anticoagulation should be administered for up to 6 months guided by repeated imaging | ||
|
||
VKA for 3 months (INR target 2–3) LMWH or DOAC (rivaroxaban, apixaban or dabigatran) for 3 months Consider VKA therapy (INR target 2–3) |
||
|
warfarin for at least 3 months the safety of anticoagulation with DOAC is uncertain empirical anticoagulation for 3 months |
|
|
||
|
VKA + low dose of aspirin for 3 months triple therapy (VKA + aspirin + clopidogrel) for 1 month, then VKA + one antiplatelet for the next 2 months triple therapy (VKA + aspirin + clopidogrel) for 3–6 months |
Then discontinue warfarin and continue DAPT for up to 12 months as per ACS recommendation |
VKA for 3 months with INR target 2–3 |